Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
4 hedge funds and large institutions have $287 invested in Sorrento Therapeutics, Inc. in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
65% less capital invested
Capital invested by funds: $826 → $287 (-$539)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
+$60 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KA
KLCM Advisors
Milwaukee,
Wisconsin
|
-$285 |
SRNE Hedge Fund Activity: Q3 2024 in Review
4 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2024, worth a combined $287 — down 65% from $826 a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SRNE and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was HighPoint Advisor Group, opening a new position worth an estimated $60. The largest seller was KLCM Advisors, exiting entirely with an estimated $285 sold.
- 4 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2024, down from 5 in Q2 2024.
- Funds reported $287 of Sorrento Therapeutics, Inc. stock for Q3 2024, down 65% quarter-over-quarter.
- 1 fund opened new Sorrento Therapeutics, Inc. positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2024 was HighPoint Advisor Group, an estimated $60 added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2024 was KLCM Advisors, an estimated $285 sold.
Based on aggregated 13F filings for Q3 2024.